Clinuvel Pharmaceuticals Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Clinuvel Pharmaceuticals de 6.9% y 9.5% por año respectivamente. Se prevé que el BPA crezca en un 6.8% al año. Se espera que la rentabilidad financiera sea de 14.6% en 3 años.

Información clave

6.9%

Tasa de crecimiento de los beneficios

6.82%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	15.1%
Tasa de crecimiento de los ingresos	9.5%
Rentabilidad financiera futura	14.63%
Cobertura de analistas	Good
Última actualización	15 Apr 2025

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Expansion Into Vitiligo Treatments And PhotoCosmetics Will Unlock Future Opportunities

Feb 09 Expansion into new therapeutic areas and markets, including vitiligo treatment and North America, is projected to drive significant revenue growth.

If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity

Aug 11

An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued

Nov 18

Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Oct 20

Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?

Jul 30

Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate

Feb 27

Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?

Dec 14

This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid

Nov 03

A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Sep 23

Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today

Jul 23

With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting

Apr 10

Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?

Mar 06

Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts

Feb 27

What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?

Feb 20

Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain

Feb 01

Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Jan 14

We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide

Dec 28

Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Dec 10

What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition

Nov 21

Previsiones de crecimiento de beneficios e ingresos

ASX:CUV - Estimaciones futuras de los analistas y datos financieros pasados (AUD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2027	116	45	49	47	6
6/30/2026	107	40	44	44	6
6/30/2025	98	40	35	41	6
12/31/2024	91	39	23	24	N/A
9/30/2024	90	37	27	30	N/A
6/30/2024	88	36	31	37	N/A
3/31/2024	85	33	34	40	N/A
12/31/2023	82	30	36	42	N/A
9/30/2023	80	30	36	40	N/A
6/30/2023	78	31	36	37	N/A
3/31/2023	74	29	39	40	N/A
12/31/2022	70	26	43	44	N/A
9/30/2022	68	24	41	42	N/A
6/30/2022	66	21	39	40	N/A
3/31/2022	62	22	33	34	N/A
12/31/2021	57	24	27	27	N/A
9/30/2021	53	24	23	23	N/A
6/30/2021	48	25	18	19	N/A
3/31/2021	43	23	N/A	N/A	N/A
12/31/2020	38	21	17	19	N/A
9/30/2020	35	18	15	16	N/A
6/30/2020	33	15	13	14	N/A
3/31/2020	32	15	N/A	N/A	N/A
12/31/2019	32	15	16	16	N/A
9/30/2019	32	16	17	17	N/A
6/30/2019	31	18	18	18	N/A
3/31/2019	29	17	16	17	N/A
12/31/2018	27	16	15	15	N/A
9/30/2018	26	15	N/A	13	N/A
6/30/2018	25	13	N/A	12	N/A
3/31/2018	21	10	N/A	10	N/A
12/31/2017	17	6	N/A	8	N/A
9/30/2017	17	7	N/A	9	N/A
6/30/2017	17	7	N/A	10	N/A
3/31/2017	14	5	N/A	7	N/A
12/31/2016	12	3	N/A	4	N/A
9/30/2016	9	0	N/A	-1	N/A
6/30/2016	7	-3	N/A	-5	N/A
3/31/2016	5	-5	N/A	-5	N/A
12/31/2015	4	-6	N/A	-5	N/A
9/30/2015	4	-8	N/A	-5	N/A
6/30/2015	3	-10	N/A	-5	N/A
3/31/2015	3	-10	N/A	-5	N/A
12/31/2014	3	-10	N/A	-5	N/A
9/30/2014	3	-8	N/A	-5	N/A
6/30/2014	3	-6	N/A	-5	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (6.9% al año) de CUV es superior a la tasa de ahorro (3%).

Beneficios vs. Mercado: Se prevé que los beneficios (6.9% al año) de CUV crezcan menos que el mercado Australian (11.8% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de CUV crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (9.5% al año) de CUV crezcan más rápidamente que los del mercado Australian (5.6% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 9.5% al año) de CUV crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de CUV sea baja dentro de 3 años (14.6%).

Descubre empresas en crecimiento

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2025/05/23 06:24
Precio de las acciones al final del día	2025/05/23 00:00
Beneficios	2024/12/31
Ingresos anuales	2024/06/30

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Clinuvel Pharmaceuticals Limited está cubierta por 10 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Thomas Wakim	Bell Potter
Norbert Kalliwoda	Dr. Kalliwoda Research
David Stanton	Jefferies LLC

Clinuvel Pharmaceuticals Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 12% to AU$24.63

Price target increased by 18% to AU$30.32

Price target decreased by 7.4% to AU$25.01

Price target increased by 13% to AU$31.12

Price target decreased by 7.2% to AU$27.50

Price target increased by 11% to AU$28.94

Recent updates

CLINUVEL Recruitment 200 Patients in Phase III Vitiligo Trial CUV105

Price target decreased by 12% to AU$24.63

Clinuvel Pharmaceuticals Limited to Report First Half, 2025 Results on Feb 27, 2025

Expansion Into Vitiligo Treatments And PhotoCosmetics Will Unlock Future Opportunities

CLINUVEL Files Canadian New Drug Submission for SCENESSE® in EPP

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 16, 2024

Dividend of AU$0.05 announced

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 17%

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

Price target increased by 18% to AU$30.32

Clinuvel Pharmaceuticals Limited Announces Change of Company Secretary

CLINUVEL Announces A Novel Clinical Program

Price target decreased by 7.4% to AU$25.01

First half 2024 earnings released: EPS: AU$0.22 (vs AU$0.23 in 1H 2023)

Clinuvel Pharmaceuticals Limited to Report First Half, 2024 Results on Feb 22, 2024

Price target increased by 13% to AU$31.12

Price target decreased by 7.2% to AU$27.50

Clinuvel Pharmaceuticals Limited Announces Board Changes

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 31, 2023

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2023, Payable on September 20, 2023

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Aug 29, 2023

If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity

Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?

Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Investor sentiment deteriorates as stock falls 20%

Now 22% undervalued

First half 2023 earnings released: EPS: AU$0.23 (vs AU$0.12 in 1H 2022)

Clinuvel Pharmaceuticals Ltd Announces the Completion of Manufacture of the First cGMP Batch of PRÉNUMBRA® Instant

Clinuvel Pharmaceuticals Limited Announces First Positive Results from Study Evaluating the Protective Effects of Afamelanotide on Skin Exposed to Ultraviolet Radiation

Price target increased by 11% to AU$28.94

Clinuvel Pharmaceuticals Limited Announces Neuracthel Manufacturing Processes Advance

Clinuvel Pharmaceuticals Limited Shares the First Results of Phase II Study Evaluating Afamelanotide in Patients with Xeroderma Pigmentosum

An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued

No independent directors

Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Clinuvel Pharmaceuticals Limited Announces Enrollment of First Patient in New Clinical Study CUV104

Investor sentiment improved over the past week

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 26, 2022

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2022, Payable on September 21, 2022

Now 20% undervalued

Investor sentiment improved over the past week

Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?

CLINUVEL PHARMACEUTICALS LIMITED Intends to Evaluate its Drug Candidate PRÉNUMBRA Instant (Afamelanotide) as A Treatment for Patients Diagnosed with Arterial Ischaemic Stroke (AIS) in its Next Clinical Trial (CUV803)

Non-Executive Director recently sold AU$356k worth of stock

CLINUVEL Progresses CUV104 Vitiligo Study

CLINUVEL Releases Positive Final Results of the Open Label Pilot Study (CUV801) in Arterial Ischemic Stroke

No independent directors

Clinuvel Pharmaceuticals Ltd Appoints Andrew Likierman as New Non-Executive Director

Clinuvel Pharmaceuticals Limited Announces First XP-V Patient Treated in Third CUV DNA Repair Study

CEO, MD & Director recently sold AU$1.1m worth of stock

Now 22% undervalued after recent price drop

Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to AU$27.32

Investor sentiment deteriorated over the past week

Clinuvel Pharmaceuticals Limited Completes Enrolment in CUV801 Stroke Study

Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?

This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid

A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Full year 2021 earnings released: EPS AU$0.50 (vs AU$0.31 in FY 2020)

Investor sentiment improved over the past week

Price target increased to AU$33.92

Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today

CEO, MD & Director recently sold AU$3.7m worth of stock

Non-Executive Director recently sold AU$692k worth of stock